Category: Press Release - Page 13 - Psychedelic Alpha

Read more about the article Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed’s Phase 2B study evaluating MM-120

Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed’s Phase 2B study evaluating MM-120

Post published:June 5, 2023
Post category:Press Release

Read more about the article Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

Post published:June 5, 2023
Post category:Press Release

Read more about the article Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development milestones

Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development milestones

Post published:June 2, 2023
Post category:Press Release

Read more about the article Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Post published:June 2, 2023
Post category:Press Release

Read more about the article Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023

Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023

Post published:June 2, 2023
Post category:Press Release

Read more about the article atai Life Sciences to Participate in Upcoming June Investor Conferences

atai Life Sciences to Participate in Upcoming June Investor Conferences

Post published:June 1, 2023
Post category:Press Release

Read more about the article Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

Post published:June 1, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Post published:May 31, 2023
Post category:Press Release

Read more about the article COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer

Post published:May 31, 2023
Post category:Press Release

Read more about the article Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

Post published:May 30, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.